

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Art Unit	1636	
			Examiner Name		
Sheet	1	of	12	Attorney Docket Number	UF.420XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,087,440	02-11-1992	Cacheris <i>et al.</i>	All
	U2	US-5,155,215	10-13-1992	Ranney	All
	U3	US-6,207,392	03-27-2001	Weiss <i>et al.</i>	All
	U4	US-2005/220714 A1	10-06-2005	Kauzlarich <i>et al.</i>	All
	U5	US-2003/0236457 A1	12-25-2003	Mericle <i>et al.</i>	All
	U6	US-2004/0023415 A1	02-05-2004	Sokolov <i>et al.</i>	All
	U7	US-2004/0067201 A1	04-08-2004	Perkins <i>et al.</i>	All
	U8	US-6,649,138	11-18-2003	Adams <i>et al.</i>	All
	U9	US-6,815,064	11-09-2004	Treadway <i>et al.</i>	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	[⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/89585 A1	11-29-2001	Biocrystal Ltd.	All	
	F2	WO 2004/066361 A2	08-05-2004	The Board of Trustees of the University of Arkansas	All	
	F3	WO 2005/041747 A2	05-12-2005	The Trustees of the University of Pennsylvania	All	
	F4					
	F5					
	F6					
	F7					

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Art Unit	1636	
			Examiner Name		
Sheet	2	of	12	Attorney Docket Number	UF.420XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U10	US-5,990,479	11-23-1999	Weiss <i>et al.</i>	All
	U11	US-6,207,392	03-27-2001	Weiss <i>et al.</i>	All
	U12	US-6,423,551	07-23-2002	Weiss <i>et al.</i>	All
	U13	US-6,699,723	03-02-2004	Weiss <i>et al.</i>	All
	U14	US-6,251,303	06-26-2001	Bawendi <i>et al.</i>	All
	U15	US-6,322,901	11-27-2001	Bawendi <i>et al.</i>	All
	U16	US-6,444,143	09-03-2002	Bawendi <i>et al.</i>	All
	U17	US-			
	U18	US-			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
			Examiner Name		
Sheet	3	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	AKERMAN, M.E. <i>et al.</i> , "Nanocrystal Targeting <i>In Vivo</i> " <i>Proceedings of Nat'l Acad. of Sci., USA</i> , October 1, 2002, pp. 12617-12621, Vol. 99, No. 20.		
	R2	ALIVISATOS, A.P., "Perspectives on the Physical Chemistry of Semiconductor Nanocrystals" <i>J. Phys. Chem.</i> , March 26, 1996, pp. 13226-13239, Vol. 100.		
	R3	ZHAO, M. <i>et al.</i> , "Differential Conjugation of Tat Peptide to Superparamagnetic Nanoparticles and Its Effect on Cellular Uptake" <i>Bioconjugate Chemistry</i> , 2002, pp. 840-844, Vol. 13, No. 4.		
	R4	ARRIAGADA, F.J. <i>et al.</i> , "Synthesis of Nanosize Silica in a Nonionic Water-in-Oil Microemulsion: Effects of the Water/Surfactant Molar Ratio and Ammonia Concentration" <i>Journal of Colloid and Interface Science</i> , 1999, pp. 210-220, Vol. 211.		
	R5	BALLOU, B. <i>et al.</i> , "Noninvasive Imaging of Quantum Dots in Mice" <i>Bioconjugate Chem.</i> , 2004, pp. 79-86, Vol. 15, No. 1.		
	R6	BECKER, W.G. <i>et al.</i> , "Photoluminescence and Photoinduced Oxygen Adsorption of Colloidal Zinc Sulfide Dispersions" <i>J. Phys. Chem.</i> , 1983, pp. 4888-4893, Vol. 87.		
	R7	BEHBOUDNIA, M. <i>et al.</i> , "Systematics in the nanoparticle band gap of ZnS and Zn _{1-x} M _x S (M= Mn, Fe, Ni) for various dopant concentrations" <i>Physical Review B</i> , 2001, pp. 035316:1-035316:5, Vol. 63.		
	R8	BENTZEN, E.L. <i>et al.</i> , "Progression of Respiratory Syncytial Virus Infection Monitored by Fluorescent Quantum Dot Probes" <i>Nano Letters</i> , 2005, pp. 591-595, Vol. 5, No. 4.		
	R9	BHARGAVA, R.N., "Doped nanocrystalline materials - Physics and applications" <i>Journal of Luminescence</i> , 1996, pp. 85-94, Vol. 70.		
	R10	BHARGAVA, R.N. <i>et al.</i> , "Optical Properties of Manganese-Doped Nanocrystals of ZnS" <i>Physical Review Letters</i> , January 17, 1997, pp. 416-419, Vol. 72, No. 3.		
	R11	YANG, H. <i>et al.</i> , "Electroluminescence from Hybrid Conjugated Polymer—CdS:Mn/ZnS Core/Shell Nanocrystal Devices" <i>J. Phys. Chem. B.</i> , 2003, pp. 9705-9710, Vol. 107.		
	R12	BOL, A.A. <i>et al.</i> , "Temperature dependence of the luminescence of nanocrystalline CdS/Mn ²⁺ " <i>Journal of Physics and Chemistry of Solids</i> , 2003, pp. 247-252, Vol. 64.		
	R13	BOL, A.A. <i>et al.</i> , "Luminescence Quantum Efficiency of Nanocrystalline ZnS:Mn ²⁺ . 2. Enhancement by UV Irradiation" <i>J. Phys. Chem. B</i> , 2001, pp. 10203-10209, Vol. 105.		

Examiner Signature	Date Considered	11/19/2010
--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/590,590
			Filing Date	August 24, 2006
			First Named Inventor	Swadeshmukul Santra
			Group Art Unit	1636
Examiner Name				
Attorney Docket Number	UF.420XC1			
Sheet	4	of	12	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R14	BOL, A.A. <i>et al.</i> , "Doped semiconductor nanoparticles - a new class of luminescent materials?" <i>Journal of Luminescence</i> , 2000, pp. 315-318, Vol. 87-89.		
	R15	BOL, A.A. <i>et al.</i> , "On the Incorporation of Trivalent Rare Earth Ions in II-VI Semiconductor Nanocrystals" <i>Chem. Mater.</i> , 2002, pp. 1121-1126, Vol. 14.		
	R16	BOL, A.A. <i>et al.</i> , "Luminescence Quantum Efficiency of Nanocrystalline ZnS:Mn ²⁺ . 1. Surface Passivation and Mn ²⁺ Concentration" <i>J. Phys. Chem. B</i> , 2001, pp. 10197-10202, Vol. 105.		
	R17	BOUSQUET, J.C. <i>et al.</i> , "Gd-DOTA: Characterization of a New Paramagnetic Complex ¹ⁿ " <i>Radiology</i> , 1988, pp. 693-698, Vol. 166.		
	R18	BRUSCHEZ, M. <i>et al.</i> , "Semiconductor Nanocrystals as Fluorescent Biological Labels" <i>Science</i> , September 25, 1998, pp. 2013-2016, Vol. 281.		
	R19	CAO, L. <i>et al.</i> , "Luminescence enhancement of core-shell ZnS:Mn/ZnS nanoparticles" <i>Appl. Phys. Letters</i> , June 10, 2002, pp. 4300-4302, Vol. 80, No. 23.		
	R20	CARAVAN, P. <i>et al.</i> , "Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications" <i>Chem. Rev.</i> , 1999, pp. 2293-2352, Vol. 99.		
	R21	CHAN, W.C.W. <i>et al.</i> , "Luminescent quantum dots for multiplexed biological detection and imaging" <i>Curr. Opin. In Biotech.</i> , 2002, pp. 40-46, Vol. 13.		
	R22	CHAN, W.C.W. <i>et al.</i> , "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection" <i>Science</i> , September 25, 1998, pp. 2016-2018, Vol. 281, No. 5385.		
	R23	DABBOUSI, B.O. <i>et al.</i> , "(CdSe) ZnS Core-Shell Quantum Dots: Synthesis and Characterization of a Size Series of Highly Luminescent Nanocrystallites" <i>J. Phys. Chem. B</i> , 1997, pp. 9463-9475, Vol. 101.		
	R24	DERFUS, A.M. <i>et al.</i> , "Probing the Cytotoxicity of Semiconductor Quantum Dots" <i>Nano Letters</i> , 2004, pp. 11-18, Vol. 4, No. 1.		
	R25	DIETZ, G.P.H. <i>et al.</i> , "Delivery of bioactive molecules in the cell: the Trojan horse approach" <i>Mol. Cell. Neurosci.</i> , 2004, pp. 85-131, Vol. 27.		
	R26	DUBERTRET, B. <i>et al.</i> , "In vivo Imaging of Quantum Dots Encapsulated in Phospholipid Micelles" <i>Science</i> , November 29, 2002, pp. 1759-1762, Vol. 298, No. 5599.		

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	5	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	GALLAGHER, D. <i>et al.</i> , "Doped zinc sulfide nanocrystals precipitated within a poly(ethylene oxide) matrix – processing and optical characteristics" <i>Journal of Crystal Growth</i> , 1994, pp. 970-975, Vol. 138.	
	R28	GAO, X. <i>et al.</i> , "In vivo cancer targeting and imaging with semiconductor quantum dots" <i>Nature Biotech.</i> , August 2004, pp. 969-976, Vol. 22, No. 8.	
	R29	GAO, X. <i>et al.</i> , "Molecular profiling of single cells and tissue specimens with quantum dots" <i>Trends in Biotech.</i> , September 2003, pp. 371-373, Vol. 21, No. 9.	
	R30	GAPONIK, N. <i>et al.</i> , "Labeling of Biocompatible Polymer Microcapsules with Near-Infrared Emitting Nanocrystals" <i>Nano Letters</i> , 2003, pp. 369-372, Vol. 3, No. 3.	
	R31	GERION, D. <i>et al.</i> , "Synthesis and Properties of Biocompatible Water-Soluble Silica-Coated CdSe/ZnS Semiconductor Quantum Dots" <i>J. Phys. Chem. B</i> , 2001, pp. 8861-8871, Vol. 105.	
	R32	GUPTA, S. <i>et al.</i> , "Phosphor efficiency and deposition temperature in ZnS:Mn A.C. thin film electroluminescence display devices" <i>Thin Solid Films</i> , 1997, pp. 33-37, Vol. 299.	
	R33	HINES, M.A. <i>et al.</i> , "Synthesis and Characterization of Strongly Luminescing ZnS-Capped CdSe Nanocrystals" <i>J. Phys. Chem.</i> 1996, pp. 468-471, Vol. 100.	
	R34	HOSHINA, T. <i>et al.</i> , "Luminescence Excitation Spectra and Their Exciton Structures of ZnS Phosphors. II. Al and Te Doped Phosphors" <i>Jpn. J. Appl. Phys.</i> , 1980, pp. 279-287, Vol. 19, abstract.	
	R35	HUBER, M.M. <i>et al.</i> , "Fluorescently Detectable Magnetic Resonance Imaging Agents" <i>Bioconjugate Chem.</i> , 1998, pp. 242-249, Vol. 9.	
	R36	IHARA, M. <i>et al.</i> , "Preparation and Characterization of Rare Earth Activators Doped Nanocrystal Phosphors" <i>J. of the Electrochem. Soc.</i> , 2000, pp. 2355-2357, Vol. 147, No. 6.	
	R37	JAISWAL, J.K. <i>et al.</i> , "Long-Term Multiple Color Imaging of Live Cells Using Quantum Dot Bioconjugates" <i>Nature Biotech.</i> , January 2003, pp. 47-51, Vol. 21.	
	R38	JAISWAL, J.K. <i>et al.</i> , "Potentials and pitfalls of fluorescent quantum dots for biological imaging" <i>TRENDS in Cell Bio.</i> , September 2004, pp. 497-504, Vol. 14, No. 9.	
	R39	JASZCZYN-KOPEC, P. <i>et al.</i> , "Excitonic Excitation Spectra in ZnS: Cl Crystal Under Pressure" <i>Journal of Luminescence</i> , 1983, pp. 319-326, Vol. 28.	

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	6	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R40	JIANG, W. et al., "Semiconductor quantum dots as contrast agents for whole animal imaging" <i>TRENDS in Biotech.</i> , December 2004, pp. 607-609, Vol. 22, No. 12.		
	R41	JIN, C. et al., "Luminescence of Mn ²⁺ doped ZnS nanocrystallites" <i>J. of Luminescence</i> , 1996, pp. 315-318, Vol. 66-67.		
	R42	JOSEPHSON, L. et al., "Near-Infrared Fluorescent Nanoparticles as Combined MR/Optical Imaging Probes" <i>Bioconjugate Chem.</i> , 2002, pp. 554-560, Vol. 13.		
	R43	JOSEPHSON, L. et al., "High-Efficiency Intracellular Magnetic Labeling with Novel Superparamagnetic-Tat Peptide Conjugates" <i>Bioconjugate Chem.</i> , 1999, pp. 186-191, Vol. 10.		
	R44	KANE, R.S. et al., "Synthesis of Doped ZnS Nanoclusters within Block Copolymer Nanoreactors" <i>Chem. Mater.</i> , 1999, pp. 90-93, Vol. 11.		
	R45	KIM, S. et al., "Near-Infrared Fluorescent Type II Quantum Dots for Sentinel Lymph Node Mapping" <i>Nature Biotech.</i> , January 2004, pp. 93-97, Vol. 22, No. 1.		
	R46	KIRCHER, M.F. et al., "A Multimodal Nanoparticle for Preoperative Magnetic Resonance Imaging and Intraoperative Optical Brain Tumor Delineation" <i>Cancer Research</i> , December 1, 2003, pp. 8122-8125, Vol. 63.		
	R47	KUBO, T. et al., "Enhancement of photoluminescence of ZnS:Mn nanocrystals modified by surfactants with phosphate or carboxyl groups via a reverse micelle method" <i>Journal of Luminescence</i> , 2002, pp. 39-45, Vol. 99.		
	R48	LARSON, D.R. et al., "Water-Soluble Quantum Dots for Multiphoton Fluorescence Imaging in Vivo" <i>Science</i> , May 30, 2003, pp. 1434-1436, Vol. 300.		
	R49	LEWIS, J.S. et al., "Control of point defects and space charge in electroluminescent ZnS:Mn thin films" <i>J. of Appl. Physics</i> , December 1, 2002, pp. 6646-6657, Vol. 92, No. 11.		
	R50	MARGERSTADT, M. et al., "Gd(DOTA): an alternative to Gd(DTPA) as a T1,2 relaxation agent for NMR imaging or spectroscopy" <i>Magn. Reson. Med.</i> , 1986, pp. 808-812, Vol. 3, No. 5, abstract.		
	R51	SMITH, D.H. et al., "New Magnetic Resonance Imaging Techniques for the Evaluation of Traumatic Brain Injury" <i>Journal of Neurotrauma</i> , 1995, pp. 573-577, Vol. 573, Vol. 12.		
	R52	MICHALET, X. et al., "Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics" <i>Science</i> , January 28, 2005, pp. 538-544, Vol. 307.		

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	7	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R53	MORAWSKI, A.M. <i>et al.</i> , "Targeted Nanoparticles for Quantitative Imaging of Sparse Molecular Epitopes With MRI" <i>Magnetic Resonance in Medicine</i> , 2004, pp. 480-486, Vol. 51.		
	R54	SCHRIER, J. <i>et al.</i> , "Simple model for magnetization ratios in doped nanocrystals" <i>J. Appl. Physics</i> , 2004, pp. 1436-1438, Vol. 95, No. 3.		
	R55	PARUNGO, C.P. <i>et al.</i> , "Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging" <i>J. Thorac. Cardiovasc. Surg.</i> , April 2005, pp. 844-850, Vol. 129, No. 4.		
	R56	PENG, X. <i>et al.</i> , "Epitaxial Growth of Highly Luminescent CdSe/CdS Core/Shell Nanocrystals with Photostability and Electronic Accessibility" <i>J. Am. Chem. Soc.</i> , 1997, pp. 7019-7029, Vol. 119.		
	R57	PINGBO, X. <i>et al.</i> , "Photoluminescence Properties of Surface-Modified Nanocrystalline ZnS: Mn" <i>Journal of Colloid and Interface Science</i> , 2000, pp. 534-539, Vol. 229.		
	R58	RUNGE, V.M. <i>et al.</i> , "MR Imaging of Rat Brain Glioma: Gd-DTPA versus Gd-DOTA ¹ⁿ " <i>Radiology</i> , 1988, pp. 835-838, Vol. 166.		
	R59	SANTRA, S. <i>et al.</i> , "TAT conjugated, FITC doped silica nanoparticles for bioimaging applications" <i>Chem. Commun.</i> , 2004, pp. 2810-2811.		
	R60	SANTRA, S. <i>et al.</i> , "Conjugation of Biomolecules with Luminophore-Doped Silica Nanoparticles for Photostable Biomarkers" <i>Anal. Chem.</i> , 2001, pp. 4988-4993, Vol. 73.		
	R61	SANTRA, S. <i>et al.</i> , "Development of novel dye-doped silica nanoparticles for biomarker application" <i>J. of Biomedical Optics</i> , April 2001, pp. 160-166, Vol. 6, No. 2, abstract.		
	R62	SANTRA, S. <i>et al.</i> , "Synthesis and Characterization of Silica-Coated Iron Oxide Nanoparticles in Microemulsion: The Effect of Nanionic Surfactants" <i>Langmuir</i> , 2001, pp. 2900-2906, Vol. 17.		
	R63	SCHALLER, R.D. <i>et al.</i> , "Tunable Near-Infrared Optical Gain and Amplified Spontaneous Emission Using PbSe Nanocrystals" <i>J. Phys. Chem. B</i> , 2003, pp. 13765-13768, Vol. 107.		
	R64	SCHMECHEL, R. <i>et al.</i> , "Photoluminescence Properties of Nanocrystalline Y ₂ O ₃ : Eu ³⁺ in Different Environments" <i>Scripta mater.</i> , 2001, pp. 1213-1217, Vol. 44.		
	R65	SCHMIDT, T. <i>et al.</i> , "Activation of 1.54 μm Er ³⁺ Fluorescence in Concentrated II-VI Semiconductor Cluster Environments" <i>Chem. Mater.</i> , 1998, pp. 65-71, Vol. 10.		

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/590,590
			Filing Date	August 24, 2006
			First Named Inventor	Swadeshmukul Santra
			Group Art Unit	1636
Examiner Name				
Attorney Docket Number	UF.420XC1			
Sheet	8	of	12	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R66	SCHROEDTER, A. <i>et al.</i> , "Ligand Design and Bioconjugation of Colloidal Gold Nanoparticles" <i>Angew. Chem. Int. Ed.</i> , 2002, pp. 3218-3221, Vol. 41, No. 17.		
	R67	SHARMA, P. <i>et al.</i> , "Nanoparticles for bioimaging" <i>Advances in Colloid and Interface Science</i> , 2006, pp. 471-485, Vol. 123-126.		
	R68	SMITH, A.M. <i>et al.</i> , "Quantum Dot Nanocrystals for <i>In Vivo</i> Molecular and Cellular Imaging" <i>Photochemistry and Photobiology</i> , 2004, pp. 377-385, Vol. 80.		
	R69	SMITH, A.M. <i>et al.</i> , "Luminescence decay kinetics of Mn ²⁺ -doped ZnS nanoclusters grown in reverse micelles" <i>Phys. Rev. B</i> , 2000, pp. 2021-2028, Vol. 62, No. 3.		
	R70	SONG, K.K. <i>et al.</i> , "Highly luminescent (ZnSe)ZnS core-shell quantum dots for blue to UV emission: synthesis and characterization" <i>Curr. Applied Physics</i> , 2001, pp. 169-173, Vol. 1.		
	R71	STAVIS, S.M. <i>et al.</i> , "Single molecule studies of quantum dot conjugates in a submicrometer fluidic channel" <i>Lab on a Chip</i> , 2005, pp. 337-343, Vol. 5.		
	R72	SUN, L. <i>et al.</i> , "Study of the optical properties of Eu ³⁺ -doped ZnS nanocrystals" <i>Journal of Alloys and Compounds</i> , 1998, pp. 234-237, Vol. 275-277.		
	R73	SUYVER, J.F. <i>et al.</i> , "Synthesis and Photoluminescence of Nanocrystalline ZnS:Mn ²⁺ " <i>Nano Letters</i> , 2001, pp. 429-433, Vol. 1, No. 8.		
	R74	SUYVER, J.F. <i>et al.</i> , "Luminescence of nanocrystalline ZnSe: Mn ²⁺ " <i>Phys. Chem. Chem. Phys.</i> , 2000, pp. 5445-5448, Vol. 2.		
	R75	TANAKA, M., "Photoluminescence Properties of Mn ²⁺ -doped II-VI Semiconductor Nanocrystals" <i>Journal of Luminescence</i> , 2002, pp. 163-173, Vol. 100.		
	R76	VAN DE RIJKE, F. <i>et al.</i> , "Up-converting phosphor reporters for nucleic acid microarrays" <i>Nature Biotechnol.</i> , March 2001, pp. 273-276, Vol. 19.		
	R77	VOURA, E.B. <i>et al.</i> , "Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy" <i>Nature Med.</i> , September 2004, pp. 993-998, Vol. 10, No. 9.		
	R78	WAGER, J.F. <i>et al.</i> , "Luminescent impurity doping trends in alternating-current thin-film electroluminescent phosphors" <i>J. of Luminescence</i> , 2002, pp. 68-81, Vol. 97.		

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	9	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	R79	WANG, Y. <i>et al.</i> , "Nanometer-Sized Semiconductor Clusters: Materials Synthesis, Quantum Size Effects, and Photophysical Properties" <i>J. Phys. Chem.</i> , 1991, pp. 525-532, Vol. 95.			
	R80	WU, X. <i>et al.</i> , "Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots" <i>Nature Biotech.</i> , January 2003, pp. 41-46, Vol. 21.			
	R81	YANG, H. <i>et al.</i> , "Syntheses and applications of Mn-doped II-VI semiconductor nanocrystals" <i>J. Nanosci. Nanotechnol.</i> , September 2005, pp. 1364-1375, Vol. 5, No. 9, abstract.			
	R82	YANG, H. <i>et al.</i> , "Photoluminescent and electroluminescent properties of Mn-doped ZnS nanocrystals" <i>J. of Appl. Phys.</i> , January 1, 2003, pp. 586-592, Vol. 93, No. 1.			
	R83	YANG, H. <i>et al.</i> , "Enhanced photoluminescence from CdS:Mn/ZnS core/shell quantum dots" <i>Appl. Phys. Lett.</i> , March 24, 2003, pp. 1965-1967, Vol. 82, No. 12.			
	R84	YANG, H. <i>et al.</i> , "Efficient and Photostable ZnS-Passivated CdS:Mn Luminescent Nanocrystals" <i>Advanced Functional Materials</i> , February 2004, pp. 152-156, Vol. 14, No. 2.			
	R85	YANG, H. <i>et al.</i> , "Water-Soluble Silica-Overcoated CdS: Mn/ZnS Semiconductor Quantum Dots" <i>J. Chem. Physics</i> , October 15, 2004, pp. 7412-7426, Vol. 121, No. 15.			
	R86	ZHELEV, Z. <i>et al.</i> , "Fabrication of quantum dot-lectin conjugates as novel fluorescent probes for microscopic and flow cytometric identification of leukemia cells from normal lymphocytes" <i>Chem. Commun.</i> , 2005, pp. 1980-1982.			
	R87	ZIJLMANS, H.J.M.A.A. <i>et al.</i> , "Detection of Cell and Tissue Surface Antigens Using Up-Converting Phosphors: A New Reporter Technology" <i>Analytical Biochemistry</i> , 1999, pp. 30-36, Vol. 267.			
	R88	DAHAN, M. <i>et al.</i> , "Diffusion Dynamics of Glycine Receptors Revealed by Single-Quantum Dot Tracking" <i>Science</i> , 2003, pp. 442-445, Vol. 302, No. 5644.			
	R89	NAM, J.M. <i>et al.</i> , "Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins" <i>Science</i> , 2003, pp. 1884-1886, Vol. 301, No. 5641.			
	R90	"Quantum Dots Could Guide Surgeons" <i>NIBIB eAdvances</i> , February 11, 2004, Retrieved 03-03-2004, from http://www.nbib.nih.gov/eAdvances/021104.htm			
	R91	SCHWARZE, S.R. <i>et al.</i> , "In Vivo Protein Transduction: Delivery of a Biologically Active Protein in the Mouse" <i>Science</i> , 1999, pp. 1569-1572, Vol. 285, No. 5433.			

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	10	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R92	AGUAYO, J.B. <i>et al.</i> , "Nuclear magnetic resonance imaging of a single cell" <i>Nature</i> , 1986, pp. 190-191, Vol. 322.	
	R93	ALIVISATOS, A. P., "Less Is More in Medicine" <i>Scientific American</i> , September 2001, pp. 66-73, Vol. 285.	
	R94	ASTRIAB-FISHER, A. <i>et al.</i> , "Conjugates of Antisense Oligonucleotides with the Tat and Antennapedia Cell-Penetrating Peptides: Effects on Cellular Uptake, Binding to Target Sequences, and Biologic Actions" <i>Pharm. Res.</i> , June 2002, pp.744-754, Vol. 19, No. 6.	
	R95	BEN-ARI, E.T., "Nanoscale Quantum Dots Hold Promise for Cancer Applications" <i>JNCI Journal of the National Cancer Institute</i> , 2003, pp. 502-504, Vol. 95, No. 7.	
	R96	BRIGGER, I. <i>et al.</i> , "Nanoparticles in cancer therapy and diagnosis" <i>Adv Drug Deliv Rev</i> , 2002, pp.631-651, Vol. 54.	
	R97	COSTOUROS, N.G. <i>et al.</i> , "Molecular Imaging of Tumor Angiogenesis" <i>Journal of Cellular Biochemistry</i> , 2002, pp. 72-78, Vol. 39 Supplement.	
	R98	DOUGLAS, S.J. <i>et al.</i> , "Nanoparticles in Drug Delivery" <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1987, pp. 233-261, Vol. 3, No. 3, abstract.	
	R99	DZIK-JURASZ, A., "The development and application of functional nuclear magnetic resonance to <i>in vivo</i> therapeutic anticancer research" <i>The British Journal of Radiology</i> , 2004, pp. 296-307, Vol. 77.	
	R100	EMERICH, D.F. <i>et al.</i> , "Nanotechnology and Medicine" <i>Expert Opinion on Biological Therapy</i> , 2003, pp. 655-663, Vol. 3, No. 4, abstract.	
	R101	FAWELL, S. <i>et al.</i> , "Tat-mediated delivery of heterologous proteins into cells" <i>Proc. Natl. Acad. Sci. USA</i> , January 1994, pp. 664-668, Vol. 91.	
	R102	FUJISAWA, T. <i>et al.</i> , "Spontaneous Emission Spectrum in Double Quantum Dot Devices" <i>Science</i> , October 30, 1998, pp. 932-935, Vol. 282.	
	R103	HELLGREN, I. <i>et al.</i> , "Factors Controlling the Efficiency of Tat-mediated Plasmid DNA Transfer" <i>Journal of Drug Targeting</i> , 2004, pp. 39-47, Vol. 12, No. 1.	
	R104	HILDEBRANDT, I.J. <i>et al.</i> , "Molecular imaging applications for immunology" <i>Clinical Immunology</i> , 2004, pp. 210-224, Vol. 111.	

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	11	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R105	HOLM, B.A. et al., "Nanotechnology in Biomedical Applications" <i>Molecular Crystals and Liquid Crystals</i> , 2002, pp. 589-598, Vol. 374.		
	R106	KALE, A. et al., "Infrared emission from zinc sulfide: Rare-earth doped thin films" <i>J. Appl. Physics</i> , September 2003, pp. 3147-3152, Vol. 94, No. 5.		
	R107	KARAR, N. et al., "Structure and photoluminescence studies on Zn:Mn nanoparticles" <i>J. Appl. Physics</i> , January 2004, pp. 656-660, Vol. 95, No. 2.		
	R108	KREEL, L., "Medical imaging" <i>Postgraduate Medical Journal</i> , 1991, pp. 334-346, Vol. 67.		
	R109	Invitrogen, "Qdot® Conjugates Protocol Handbook" Quantum Dot Invitrogen nanocrystal technologies, December 12, 2005.		
	R110	LANGER, S.G. et al., "Imagine Acquisition: Ultrasound, Computed Tomography, and Magnetic Resonance Imaging" <i>World Journal of Surgery</i> , 2001, pp. 1428, Vol. 25.		
	R111	PANYAM, J. et al., "Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles" <i>International Journal of Pharmaceutics</i> , 2003, pp. 1-11, Vol. 262.		
	R112	SANTRA, S. "Integrated fluorescent, radio-opaque and magnetic nanoparticles for intra-arterial pre-operative brain mapping and broad based diagnostic imaging" abstract presented at Florida Research Consortium 2004 Technology Transfer Conference, May 17-18, 2004, St. Petersburg, FL.		
	R113	SANTRA, S. "Multimodal quantum dots for non invasive diagnosis and real time gross visualization of brain tumors" presented at Florida Research Consortium-Tech Transfer Conference, May 18-19, 2005, Orlando, FL.		
	R114	SANTRA, S. et al. "Development of TAT (a cell penetrating peptide) conjugated fluorescent nanoparticles for preoperative intra-arterial brain mapping" abstract presented at American Association of Neurological Surgeons 2004 Annual Meeting, May 4, 2004, Orlando, FL.		
	R115	SANTRA, S. "Multifunctional nanoparticles for in vivo bioimaging applications" July 2, 2004.		
	R116	SANTRA, S. et al., "Synthesis and Characterization of Fluorescent, Radio-Opaque, and Paramagnetic Silica Nanoparticles for Multimodal Bioimaging Applications", <i>Advanced Materials</i> , 2005, pp. 2165-2169, Vol. 17.		
	R117	SANTRA, S. et al., "Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots" <i>Chem. Commun.</i> , 2005, pp. 3144-3146.		

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,590	
			Filing Date	August 24, 2006	
			First Named Inventor	Swadeshmukul Santra	
			Group Art Unit	1636	
Examiner Name					
Sheet	12	of	12	Attorney Docket Number	UF.420XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R118	SANTRA, S. <i>et al.</i> , "Synthesis of Water-Dispersible Fluorescent, Radio-Opaque, and Paramagnetic CdS:MnZnS Quantum Dots: A Multifunctional Probe for Bioimaging" <i>J. Am. Chem. Soc.</i> , 2005, pp. 1656-1657, Vol. 127.	
	R119		
	R120		
	R121		
	R122		
	R123		
	R124		
	R125		
	R126		
	R127		
	R128		

Examiner Signature	/Leah Schlientz/	Date Considered	11/19/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.